LBI-HTA - Publications - Search - Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma

Nachtnebel, A. (2009): Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma. DSD: Horizon Scanning in Oncology 05.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
218Kb
Abstract

Radioimmunotherapy with ibritumomab tiuxetan offers a treatment option for consolidation therapy in previously untreated patients with follicular lymphomas. Administration of Zevalin® after induction chemotherapy prolonged progression free survival in comparison to no further treatment in a phase III trial. Since only the minority of patients included in this trial had received rituximab based regimens prior to ibritumomab tiuxetan, standard practice is not reflected.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Ibritumomab tiuxetan. Zevalin, Oncology, follicular lymphoma, non-Hodgkin’s lymphoma, NHL, indolent lymphoma
Subjects:WN Radiology. Diagnostic imaging
WH Hemic and lymphatic systems
QZ Pathology > QZ 200-380 Neoplasms.Cysts
Language:English
Series Name:DSD: Horizon Scanning in Oncology 05
Deposited on:02 Nov 2009 16:48
Last Modified:02 Nov 2009 16:48

Repository Staff Only: item control page